Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

Key Takeaway: Alkermes has announced that Alixorexton has received orphan drug designations in both the U.S. and Europe. This designation is intended to facilitate the development of the drug for rare diseases. The announcement highlights Alkermes' commitment to addressing unmet medical needs in these regions.